Recent data from Phesi, a clinical development analytics company, reveals a significant shift in medical research priorities. Type 2 diabetes has emerged as one of the top five most studied diseases globally in the first half of 2024, surpassing COVID-19. Breast cancer, solid tumors, stroke, and prostate cancer are the top five.
This change coincides with a surge in investment in GLP-1 therapies, such as Ozempic and WeGovy, to address the rising prevalence of obesity. Over 40% of US adults and more than one-quarter of UK adults are now classified as obese.
Phesi’s report highlights another concerning trend: increased clinical trial attrition rates. Approximately 32% of Phase II trials were terminated in the first half of 2024, a significant 56% rise compared to pre-pandemic levels.
This data was gathered from an analysis of 66,935 clinical trials utilizing Phesi’s Trial Accelerator™ platform, incorporating data from over 120 million patients in numerous cohorts.
Source link: https://www.phesi.com/
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
5 Comments
Akeso Doses First Patient in AK146D1 Phase II Study for Advanced NSCLC
1 month ago[…] NSCLC is intensifying. Datopotamab deruxtecan received FDA approval in May 2026 for triple-negative breast cancer, and single-target TROP2 ADCs are advancing across multiple tumor types. Akeso’s bispecific […]
What the MASAI Trial Correspondence in The Lancet Actually Says About AI Screening Evidence
1 month ago[…] that raise concern” is doing heavy analytical work in a short space. Overdiagnosis in breast cancer screening refers to the detection of cancers that would never have caused symptoms or death in the […]
AI Site Selection Sounds Fast — Until You See What Happens After the Algorithm Picks Your Site
1 month ago[…] your site using an AI platform, ranked your PI’s publication history, mapped your metastatic breast cancer patient volume from claims data, and slotted you into a projected enrollment curve. Congratulations […]
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
1 month ago[…] of 30 November 2026, and the clinical logic behind that designation is hard to dispute: the lidERA Breast Cancer trial enrolled over 4,100 patients with medium- or high-risk stage I–III ER-positive, […]
Decentralized Trials Are Everywhere. Nobody Agrees What They’re For.
1 month ago[…] — a fully decentralized study in patients with advanced estrogen-receptor positive, HER2-negative breast cancer. The design was built on the premise that removing the site visit barrier would unlock an […]
Comments are closed.